Key Takeaways
- Realization-led recovery, not volume: Revenue and margins rebounded sharply as import pressure eased, with realization up ~25% QoQ, while volumes stayed at ~60% utilization. The quarter’s growth was almost entirely price-driven.
- Dumping relief is fragile and exogenous: Chinese dumping has declined, lifting domestic realizations, but management calls the sustainability a business risk it cannot predict and is deliberately avoiding debt or aggressive expansion because of it.
- Isostearic acid is the long-dated option: The company is only the third manufacturer globally, using a green process, but cosmetic buyer qualification is slow. A breakthrough with even one large buyer would be material, but the timeline remains uncertain.
- New capacity and products are coming, details are not: A 40,000 MT plant is starting trial runs with margins expected above current levels, and a new raw material launches next quarter, but management declined to name either product.
- What to watch next quarter: Whether the 5–7% quarterly volume ramp materializes, any update on Isostearic acid buyer qualification, and whether improved realizations hold if the West Asia supply disruption eases.
The Quarter: Realization Surge on Import Relief
- Price pass-through worked: Elevated raw material costs were passed on to consumers because imports reduced due to Middle East geopolitical supply chain issues, directly improving domestic realizations.
- Realization jump quantified: Realization from Q4 FY26 went up ~25% and from Q1 FY26 went up ~30%, per an analyst’s math. Management confirmed most growth this quarter was realization-led, not volume-led.
- Volume restraint was deliberate: Two quarters back, management refused to sell at prices domestic competitors were offering for dimer acid and linoleic acid, keeping utilization at 35–40%. Now with better realizations, they are comfortable ramping up.
- Energy costs structurally lower: A major energy conservation exercise last year reduced power consumption by over 30% and solid fuel consumption by over 35%, providing a permanent cost-base improvement.
- Import trend supportive: Quantities of imports are going down and prices are going up, reinforcing the domestic pricing environment.
Nahoosh Jariwala: "Basically, there was dumping happening from China, which has gone down. And if dumping starts again, we cannot do anything about it."
The Dumping Overhang: Margin Structure and Risk
- Inverted duty structure bleeds margin: Finished product duty at 7.5% versus raw material duty at 16.5% creates a 9% differential that directly reduces margins. This inverted duty structure came into effect in 2024 at 27.5%, then was reduced to 16.5%.
- No split available: Management did not provide a breakdown of how much margin sacrifice comes from the inverted duty structure versus dumping, only explaining the 9% differential.
- Too small to lobby: When asked whether representations have been made to correct the inverted duty structure, management responded they are “too small to try to understand this duty thing.”
- Expansion philosophy shaped by risk: The company is not doing any aggressive expansion or taking on debt specifically because the sustainability of reduced dumping is uncertain and treated as an unhedgeable business risk.
Nahoosh Jariwala: "It will be something which is happening in China. What type of thought process is going on there? So, I might say that yes, this is sustainable. It might not and it might remain sustainable also. So, I mean, this is a business risk. So, that is one of the reasons we are not doing any crazy expansion or we are not taking any debt or anything."
Isostearic Acid: The Strategic Differentiator
- Third in the world, green route: The company is the third manufacturer globally of Isostearic acid and follows a green process, which management calls its USP. The green route is also why buyer stability tests are taking longer.
- Qualification grind: Entry barriers are stringent because the product is used in cosmetics in Europe and Japan with very strict companies. At a couple of companies, all five qualification steps are finished; at a couple, at the fourth step; everywhere has crossed the third step.
- Breakthrough economics: The ramp-up will be lumpy: a breakthrough comes when even one buyer enters in a big way. Once entered, it is a long-term association with high switching costs.
- Capacity utilization link: Isostearic acid introduction is intended to increase dimer fatty acid plant utilization, which in turn increases overall plant capacity utilization.
- VAGUE-TIMELINE: Management expects some positive outcome by end of FY27, but the qualification process has no fixed timeline and the company is moving slowly to avoid undue risk.
Nahoosh Jariwala: "The beauty is that only third manufacturer in the world. So, it also would have its own entry barrier because the products are used in cosmetics in Europe and Japan which are very, very, very strict companies to deal with. So, that is taking more time. But once you enter, it's a long-term association with them. So, that's fine with us. We don't mind."
New Products and Capacity: Known Unknowns
- 40,000 MT trial run starting: A new oleochemical family product plant with 40,000 metric ton capacity is starting trial runs, with ramp-up to follow after stabilization. Margins are expected to be better than current levels.
- New raw material launch next quarter: In Q2 FY27, the company will introduce one new raw material manufactured for the first time, falling in the oleochemical sector, with the process developed by the in-house R&D lab.
- Product identities withheld: Management declined to name the product assigned to the 40,000 MT capacity or the new raw material, stating it would not diverge at this stage.
- Linoleic acid upgradation in trials: An upgraded linoleic acid product using oil-sealed railings is undergoing customer trials, with price realization expected to be better than normal linoleic acid, though the magnitude will only be known once contracts are entered.
- Strategic direction articulated: Over the next 2–3 years, the company plans to move into products that are difficult to manufacture, not application-specific products like peers.
Nahoosh Jariwala: "Difficult to manufacture. Difficult to manufacture."
Volume Ramp and Market Positioning
- Quarterly ramp target: Management plans to increase capacity utilization every quarter by ~5%, targeting a 70–75% exit rate for FY27 from the current ~60%. Quantity is intended to grow 5–7% each quarter, cumulating to 15–20% growth by Q4 FY27.
- Paint industry dependence stays: No intention to reduce dependence on the paint industry, which currently accounts for 40% of domestic revenue via linoleic acid. The plan is to increase overall capacity utilization across the board.
- Linoleic acid as crude vegetable oil substitute: When crude vegetable oil prices reduce, the company’s costs also reduce, providing a natural hedge in the paint industry value chain.
- Export growth drivers identified: Dimer and Isostearic acid are the key products targeted for export growth, supported by the concluded India-UK FTA, expected India-EU FTA, favorable US tariff developments, and recent INR depreciation.
- No long-term contracts in volatility: Management will not enter into long-term contracts given current volatility, describing doing so as “hara-kiri.”
- Market share first, then capacity: The first step is to reach 100% capacity utilization at current realization levels, then ramp up capacity further.
Nahoosh Jariwala: "I would not like to enter into any long-term contract with so much volatility. It would be hara-kiri for me."
R&D and Cost Optimization
- In-house technology development: None of the technologies the company pursues are available off the shelf; all are self-developed. The R&D approach is deliberately slow to avoid undue risk, with no fixed time spans.
- Catalyst optimization underway: The company has started working on different types of catalysts to reduce consumption and value.
- R&D expense disclosure gap: An analyst noted R&D capital and recurring expenses showed blank in the annual report. Management said R&D expense is already mentioned and they will get back, but the analyst maintained they could not find it clearly.
Nahoosh Jariwala: "R&D is something which takes pretty long and in which time span is not fixed... none of these technologies are available off the shelf. All these technologies are to be self-developed. So, rather than taking any undue risk, we try to move slowly."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue and margin run rate | Maintain similar revenue and margin run rate as Q1 FY27 | Rest of FY27 (three quarters) |
| Capacity utilization exit rate | Reach 70–75% utilization from current ~60% | FY27 exit |
| Quarterly quantity growth | Grow quantity 5–7% QoQ, cumulating to 15–20% growth | By Q4 FY27 |
| Isostearic acid capacity utilization | Reach >80% capacity utilization | Next 1–2 years |
| New raw material introduction | Introduce one new raw material manufactured for first time | Q2 FY27 |
| 40,000 MT new capacity | Trial run starting, ramp-up after stabilization; margins expected better than current | Ramp-up timeline not specified |
| Strategic product mix shift | Move into products that are difficult to manufacture, not application-specific | Next 2–3 years |
| Isostearic acid buyer breakthrough | Expect some positive outcome | By end of FY27 (VAGUE-TIMELINE) |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹176 crores, +34.4% YoY |
| EBITDA | ₹18 crores |
| EBITDA margin | 10.14% |
| Net profit | ₹10 crores |
| Sales volume | 13,500 tonnes, vs 13,000 tonnes in Q1 FY26 |
| Raw material processed | 12,400 tonnes |
| Realization growth | +30% YoY, +25% QoQ |
| Capacity utilization | ~60%, target to exit FY27 at 70-75% |
| Revenue mix: Dimer acid | ~30% of revenue |
| Revenue mix: Linoleic acid | 42% of revenue |
| Revenue mix: Isostearic acid | 4% of revenue |
| Revenue mix: Other by-products | 24% of revenue |
| Export revenue contribution | 7-8% of revenue |
| Domestic paint industry revenue | 40% of domestic revenue |
| Isostearic acid capacity utilization target | >80% in next 1-2 years |
| Quantity growth target | 5-7% per quarter, 15-20% by Q4 FY27 |